Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03602911 · ClinicalTrials.gov registry record · Phase 2
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
A Phase 2 study, sponsored by West Virginia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03602911: Completed Phase 2 study, sponsored by West Virginia University.
NCT03602911 is a Phase 2 study that has completed, run by West Virginia University. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03602911, a Phase 2 study, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.
Primary Outcome
NETSPOT imaging will be at least equivalent to 18F FDG PET/CT in the detection and staging of HNSCC. This will be done using Standard Uptake Value (SUV) measurements. SUV max of \> 2.5 for 18F-FDG-PET and \> 1.5 for 68GA DOTATATE-PET/CT were used as thresholds of concern. Using the PET scan, investigators calculated the standard uptake value (SUV), to compare the amount of an agent injected into the patient and the amount taken up by the tumor.
Interventions
- DRUG The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
What the finished NCT03602911 record still lists
NCT03602911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT is the first listed.
NCT03602911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03602911 about?
NCT03602911 is a clinical study titled "A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients". This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.
What is the current status of trial NCT03602911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-02-01. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT03602911?
The interventions under investigation include: The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT (DRUG).
Who is sponsoring clinical trial NCT03602911?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03602911's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI